DNA甲基化/去甲基化调控缺血性卒中的研究进展OACSTPCD
Research advances in DNA methylation/demethylation in regulating ischemic stroke
卒中是我国首位的致死致残原因,其中急性缺血性卒中(ischemic stroke,IS)约占全部卒中的80%,是一种具有遗传背景的复杂疾病.脱氧核糖核酸(deoxyribonucleic acid,DNA)甲基化/去甲基化是表观遗传的重要方式之一,近年研究发现其在IS的发病和复发中发挥重要作用,预示着DNA甲基化/去甲基化分子有望成为IS新的诊断标志物和药物治疗靶点.现将DNA甲基化/去甲基化在缺血性卒中的研究进展进行综述.
Stroke is the leading cause of death and disability in China.Ischemic stroke(IS)is the dominantsubtype of stroke with a proportion more than 80%.Certainly,IS is a complex disease with a ge-neticpredisposition.DNA methylation/demethylation is a crucial epigenetic mechanism,which has been found to play an important role in the pathogenesis and recurrence of IS in recent years,indicating that DNA methylation/demethylation may be potential diagnostic biomarker and therapeutic targets for IS.The latest advances of DNA methylation/demethylation in IS is summarized as follows.
李亚楠;韩非原;王文;伍昊文;孙宏巍
哈尔滨医科大学附属第一医院神经内科,黑龙江 哈尔滨 150001
临床医学
缺血性卒中表观遗传学DNA甲基化DNA去甲基化
Ischemic strokeEpigeneticsDNA methylationDNA demethylation
《中风与神经疾病杂志》 2024 (001)
47-51 / 5
哈尔滨医科大学附属第一医院科研创新基金(2020B05);黑龙江省级大学生创新创业项目(S202210226012)
评论